Global Oncology Molecular Diagnostics Market Analysis 2025-2030: Growth Drivers, Challenges, And Opportunities

The Oncology Molecular Diagnostics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Oncology Molecular Diagnostics Market Size During the Forecast Period?
The oncology molecular diagnostics market has grown rapidly in recent years. It is expected to increase from $4.84 billion in 2024 to $5.65 billion in 2025, with a compound annual growth rate (CAGR) of 16.7%. This growth is supported by the introduction of early tests, advancements in genomic profiling, the emergence of next-generation sequencing (NGS), early biomarker identification, and the development of targeted therapies.

The oncology molecular diagnostics market is set to grow rapidly, reaching $8.99 billion by 2029 at a CAGR of 12.3%. The growth will be driven by advancements in liquid biopsy, companion diagnostics, artificial intelligence integration, expansion of next-generation sequencing (NGS), and evolving biomarker identification. Trends include global accessibility, regulatory framework improvements, and patient-focused care models.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3457

What Are the High-Growth Segments in the Oncology Molecular Diagnostics Market?
The oncology molecular diagnostics market covered in this report is segmented -

1) By Product: Instruments, Reagents, Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic & Research Institutes, Other End Users

Subsegments:
1) By Instruments: PCR (Polymerase Chain Reaction) Machines, Sequencers, Microarray Platforms, Fluorescence In Situ Hybridization (FISH) Instruments
2) By Reagents: DNA And RNA Extraction Kits, PCR Reagents And Kits, NGS Library Preparation Kits, Diagnostic Assay Reagents
3) By Other Products: Software For Data Analysis And Interpretation, Quality Control And Calibration Products, Consumables, For Molecular Testing, Biomarkers For Oncology Testing

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3457&type=smp

What Key Drivers Are Expected to Influence Future Oncology Molecular Diagnostics Market Growth?
The increasing number of cancer cases globally is likely to contribute to the growth of the oncology molecular diagnostics market. In the U.S., 1.9 million new cancer cases and 609,360 cancer-related deaths were projected in 2022. The global rise in cancer cases is expected to increase the demand for oncology molecular diagnostics, thereby fueling market growth in the coming years.

Which Companies Hold the Largest Share Across Different Oncology Molecular Diagnostics Market Segments?
Major companies operating in the oncology molecular diagnostics market include F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton dic*kinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.

What Oncology Molecular Diagnostics Market Trends Are Gaining Traction Across Different Segments?
Advances in genomics technology are reshaping the oncology molecular diagnostics market. For example, OncoHelix-CoLab, launched in May 2024 at Burjeel Medical City in the UAE, specializes in genomic and immunologic profiling for cancer treatment. It provides advanced molecular diagnostics and immune profile testing, improving diagnostic accuracy and efficiency by conducting complex tests locally instead of abroad.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

What Are the Emerging Geographies for The Oncology Molecular Diagnostics Market Growth?
The countries covered in the oncology molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Oncology Molecular Diagnostics Market?
2. What is the CAGR expected in the Oncology Molecular Diagnostics Market?
3. What Are the Key Innovations Transforming the Oncology Molecular Diagnostics Industry?
4. Which Region Is Leading the Oncology Molecular Diagnostics Market?

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.